Orphan Exclusivity Dilemma: Without Legislative Fix, US FDA May Seek New Regulation
Executive Summary
FDA didn’t get policy rider it wanted which would have reversed the Catalyst court ruling that the agency cannot limit a drug’s orphan exclusivity to its approved indication. One attorney says the clearest path forward is for FDA to issue new rulemaking and face additional litigation.